Lupin and Boehringer lngelheim partner to develop and commercialize Novel Oncology Drug
(04 Sep 2019)
Boehringer lngelheim and Lupin announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor
compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The
partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer
lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad
range of oncogenic KRAS mutations.